Sandra Poole

Sandra Poole, MASc, P.Eng

Sandra joined Mythic Therapeutics in July 2020 as Chief Operating Officer, bringing more than 25 years of biopharma industry experience in strategic and operational areas including advanced therapy and biological drug development, manufacturing, business operations, and company building.  Prior to Mythic, she served as Chief Operating Officer of LogicBio Therapeutics, and Executive Vice President of Technical Operations and Commercial Development at ImmunoGen, Inc.

Before Immunogen, she spent over 15 years in leadership roles at Genzyme Corporation (acquired by Sanofi) including Vice President and General Manager of Genzyme Flanders in Belgium, and Senior Vice President of Biologics Manufacturing, overseeing global commercial manufacturing of six biologics across five manufacturing sites in the US and EU.

Sandra currently serves on the board of directors of Travere Therapeutics, was formerly on the board of directors of Viacyte, Inc. (until its acquisition by Vertex) and she served on the supervisory board for Valneva, SE.  Sandra holds both a B.A.Sc and M.A.Sc in chemical engineering from the University of Waterloo (Canada).